Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | TSPO | P30536 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424292 | 1.00 | ADORA3 (0.60) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL1423937 | 0.99 | ADORA3 (0.61) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL1423691 | 0.96 | ADORA3 (0.58) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL29501901 | 0.83 | ADORA3 (0.60) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970121 | 0.81 | ADORA3 (0.56) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL1423696 | 0.80 | ADORA3 (0.85) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL1424257 | 0.79 | ADORA3 (0.84) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL31040981 | 0.79 | ADORA3 (0.86) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL936823 | 0.79 | ADORA3 (0.86) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL1423980 | 0.79 | ADORA3 (0.86) | ADORA3ADORA1ADORA2ATMEM97DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326978-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-03 | — | — | US | disclosed |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2013-08-01 | — | — | US | disclosed |
| US-8420664-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1983990-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | US GOV HEALTH & HUMAN SERV (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | THE GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.